Senescent cells can be reduced through a combination of exercise, dietary compounds, intermittent fasting, and experimental drug therapies. No FDA-approved senolytic drug exists yet for the sole purpose of clearing these cells, but clinical trials are actively testing several promising approaches, and some strategies you can start today have real evidence behind them.
Senescent cells are old, damaged cells that stop dividing but refuse to die. They accumulate with age and pump out a toxic mix of inflammatory signals, including interleukins (IL-6, IL-8, IL-1), tumor necrosis factor, and tissue-degrading enzymes. This cocktail, known as the senescence-associated secretory phenotype (SASP), doesn’t just sit quietly. It actively damages neighboring healthy cells and can push them into senescence too, creating a spreading cycle of dysfunction linked to everything from joint degeneration to cognitive decline.
Why Senescent Cells Are Hard to Kill
The reason senescent cells stick around is that they’ve essentially hacked their own survival programming. They ramp up production of anti-death proteins from the BCL-2 family, including BCL-2 and BCL-XL, which block the normal self-destruct signals every damaged cell is supposed to obey. They also activate the PI3K/AKT survival pathway and manipulate the p53 system, a key regulator that normally decides whether a damaged cell gets repaired or eliminated.
This creates a frustrating paradox: senescent cells are too damaged to function, but too well-defended to die. Every current strategy for removing them works by disabling one or more of these survival shields, tipping the cell back toward programmed death while leaving healthy cells untouched.
Exercise: The Most Accessible Approach
Resistance exercise is the most immediately actionable way to reduce your senescent cell burden, and the effect is surprisingly fast. A single bout of resistance training triggers an immune response in skeletal muscle that specifically targets senescent cells. The mechanism works like this: lifting heavy loads damages muscle fibers just enough to send out distress signals, which recruit immune cells called phagocytic macrophages into the tissue. These macrophages recognize and engulf senescent cells on contact.
In one study, the number of senescent cells marked by the aging biomarker p16 dropped by 48% in skeletal muscle within 48 hours after a single resistance exercise session. That’s a striking reduction from one workout. The key detail is that this clearance is immune-driven. Resistance exercise essentially weakens senescent cells and flags them for destruction by your body’s own cleanup crew. This makes strength training not just a way to build muscle, but a form of internal housekeeping that becomes more important with age.
Intermittent Fasting and Senescence Genes
Prolonged intermittent fasting, roughly 17 to 19 hours per day, appears to dial down the genetic machinery that maintains the senescent state. In a study of healthy young men who fasted for this duration daily over 30 days, expression of three major senescence genes (p16, p21, and p53) all decreased significantly by the end of the observation period. The fasting also activated autophagy genes like ATG5 and ULK1, which govern your cells’ internal recycling system.
The effects were time-dependent, not immediate. Some inflammatory markers actually increased in the early weeks before declining later, suggesting the body goes through an adjustment period. This pattern is important if you’re considering extended fasting protocols: short experiments of a few days likely won’t produce the same senescence-reducing effects seen over a full month of consistent practice. The body appears to need sustained fasting exposure before the anti-senescence benefits kick in.
Senolytic Compounds: Dasatinib and Quercetin
The most studied pharmaceutical approach to senescent cell removal is the combination of dasatinib and quercetin, often abbreviated D+Q. Dasatinib targets multiple survival pathways that senescent cells depend on, particularly tyrosine kinases. Quercetin, a plant flavonoid found in onions, apples, and capers, inhibits the PI3K pathway. Together, they disable enough of the cell’s defenses to trigger self-destruction.
Clinical trials use an intermittent dosing protocol that’s quite different from how most drugs are taken. In a Phase 2 trial for skeletal health, participants took 100 mg of dasatinib daily for two consecutive days plus 1,000 mg of quercetin daily for three consecutive days, then took nothing for the remaining 25 days of each 28-day cycle. This pattern repeated five times over 20 weeks, meaning participants only took medication on 10 to 15 total days across nearly five months. The intermittent approach matters because senescent cells don’t regenerate quickly once killed, so brief treatment windows with long rest periods can clear them without the side effects of continuous dosing.
Early clinical results are encouraging for safety. A pilot study in patients at risk for Alzheimer’s disease found D+Q to be well-tolerated, and a small study in early Alzheimer’s patients confirmed that dasatinib penetrates into cerebrospinal fluid, meaning it can reach senescent cells in the brain. However, the exclusion criteria in these trials reveal caution: people with heart disease, liver disease, blood clotting issues, or those taking blood thinners, certain antibiotics, or psychiatric medications were not eligible. Dasatinib is metabolized by specific liver enzymes, and interactions with other drugs are a real concern.
It’s worth noting that dasatinib is an FDA-approved cancer drug (sold as Sprycel), but it is not approved specifically as a senolytic for aging. Using it off-label for senescent cell clearance remains experimental.
Fisetin: A Natural Alternative Under Study
Fisetin, a flavonoid found in strawberries, apples, and persimmons, has generated significant interest as a more accessible senolytic. It works through similar pathways as quercetin but appears to have stronger senolytic activity in some cell types. A Phase 2 clinical trial in breast cancer survivors is testing oral fisetin at 20 mg per kilogram of body weight, taken on days one through three of 14-day cycles for four cycles total. For a 70 kg (154-pound) person, that translates to 1,400 mg per day during dosing periods.
The trial is specifically measuring fisetin’s effect on circulating markers of senescence, which should provide the clearest human data yet on whether this supplement actually reduces senescent cell burden. Until those results are published, fisetin remains promising but unproven in humans. Supplement-grade fisetin is widely available, but the doses used in research are substantially higher than what most commercial capsules contain, and bioavailability (how much your body actually absorbs) is a known limitation with flavonoids.
Experimental Immune Therapies
One of the most precise approaches in development uses engineered immune cells, specifically CAR T cells, to hunt and kill senescent cells. Researchers identified that senescent cells display high levels of a surface protein called uPAR. By programming T cells to recognize uPAR, they created an immune therapy that selectively destroyed senescent cells in mouse models of liver fibrosis. A separate approach targets another surface marker common on senescent cells, called NKG2D ligands, and has been shown to eliminate senescent cells in aged mice and improve physical function.
The advantage of immune-based approaches is precision. Unlike drugs that temporarily disable survival pathways and hope the right cells die, engineered T cells actively seek out cells displaying senescence markers. The potential downside is that a single infusion of CAR T cells could provide long-lasting surveillance, essentially giving your immune system a permanent upgrade in its ability to detect and remove senescent cells. This technology remains in early research stages and is years from clinical availability, but it represents a fundamentally different strategy from drug-based senolytics.
Measuring Your Senescent Cell Burden
One practical challenge is that there’s currently no simple clinical test to measure how many senescent cells you carry. Researchers use panels of 35 or more blood proteins associated with senescence, including inflammatory markers like IL-6, tissue-degrading enzymes like MMP1 and MMP9, and the surface marker uPAR. These are measured using specialized immunoassay platforms not typically available in standard medical labs.
The gene p16INK4a is considered one of the most reliable markers of cellular senescence and is known to increase rapidly after events like chemotherapy. But circulating protein levels in blood are still being validated as accurate reflections of actual senescent cell counts in tissues. Confirmation that blood markers reliably track tissue-level senescence will require larger clinical trials of senolytic treatments. For now, most people pursuing senolytic strategies are doing so based on age and health status rather than a specific test result.
A Practical Starting Point
If you’re looking to reduce your senescent cell load today, the evidence most strongly supports regular resistance training, which can cut senescent cells in muscle tissue by nearly half within two days of a single session. Adding a prolonged intermittent fasting practice of 17 or more hours daily may further reduce senescence gene expression over weeks to months. Quercetin and fisetin are available as supplements, though the doses shown to have senolytic effects in research (1,000 mg of quercetin, 20 mg/kg of fisetin) are higher than typical supplement recommendations, and their effectiveness outside of clinical protocols with dasatinib is less clear.
Pharmaceutical senolytics like dasatinib plus quercetin are being tested in clinical trials for conditions ranging from Alzheimer’s disease to pulmonary fibrosis to multiple sclerosis. These remain investigational treatments with meaningful drug interaction risks and are not something to self-prescribe. The intermittent dosing model used in trials, just a few days of treatment per month, reflects the unique biology of senescent cells: once cleared, they take time to reaccumulate, making aggressive continuous treatment unnecessary and potentially harmful.